LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Elenco Azioni・Arcutis Biotherapeutics Inc
Search

Arcutis Biotherapeutics Inc

Chiusa

SettoreSettore sanitario

23.22 2.16

Fortemente da comprare

Aggiornamento del prezzo 10 giu 2026, 19:59 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

22.23

Massimo

23.97

Metriche Chiave

By Trading Economics

Entrata

-29M

-11M

Vendite

-24M

105M

EPS

-0.09

Margine di Profitto

-10.717

Dipendenti

354

EBITDA

-31M

-8.5M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+52.83% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-282M

2.7B

Apertura precedente

21.06

Chiusura precedente

23.22

Notizie sul Sentiment di mercato

By Acuity

14%

86%

21 / 344 Classifica in Healthcare

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 giu 2026, 23:36 UTC

Utili

Correction to Oracle Reports Higher 4Q Profit Article

DJ

LeggI

10 giu 2026, 23:19 UTC

Azioni calde

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

LeggI

10 giu 2026, 23:09 UTC

I principali Market Mover

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

LeggI

10 giu 2026, 23:04 UTC

Utili

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

LeggI

10 giu 2026, 20:44 UTC

I principali Market Mover

Caterpillar Raises Quarterly Dividend 8%

DJ

LeggI

10 giu 2026, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

LeggI

10 giu 2026, 23:47 UTC

Discorsi di Mercato

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

LeggI

10 giu 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

LeggI

10 giu 2026, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

LeggI

10 giu 2026, 23:32 UTC

Discorsi di Mercato

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

LeggI

10 giu 2026, 23:20 UTC

Discorsi di Mercato

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

LeggI

10 giu 2026, 22:05 UTC

Discorsi di Mercato

Correction to Bank of Canada Stays on Hold Market Talk

DJ

LeggI

10 giu 2026, 21:57 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:52 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:35 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:22 UTC

Utili

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:39 UTC

Discorsi di Mercato
Utili

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

LeggI

10 giu 2026, 20:34 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Utili

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

LeggI

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

52.83% in crescita

Previsioni per 12 mesi

Media 34.83 USD  52.83%

Alto 36 USD

Basso 34 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

21 / 344 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Altri titoli del settore

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat